<DOC>
	<DOC>NCT00952393</DOC>
	<brief_summary>The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.</brief_summary>
	<brief_title>Nicotinic Receptors and Schizophrenia</brief_title>
	<detailed_description>3-2,4 dimethoxybenzylidene will be compounded with a methyallose compound in doses of 150 and 300 mg. The capsules will be administered singly and eventually bid to determine if sustained blood levels comparable to steady state blood levels seen in previous studies can be determined. Safety and EEG effects will be measured.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy volunteers: males and females who are incapable of pregnancy Medical illnesses requiring acute treatment History of seizures Substance abuse including nicotine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>receptors nicotinic</keyword>
</DOC>